Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A fixed-dose combination product consisting of **cyclosporine** (an immunosuppressant calcineurin inhibitor) and **carboxymethylcellulose** (a cellulose derivative used as an ocular lubricant/artificial tear). Cyclosporine functions by inhibiting T-cell activation and reducing inflammatory cytokine production on the ocular surface, thereby increasing tear production in patients with ocular surface disease such as dry eye. Carboxymethylcellulose acts as a hydrophilic polymer for tear film stabilization and symptomatic relief of dryness. The combination is used primarily for the treatment of dry eye disease, especially in cases of underlying ocular surface inflammation. Clinical studies and practice use involve topical administration of both agents, usually cyclosporine 0.05% (Restasis, Allergan) and carboxymethylcellulose 0.5% (as in Refresh Plus or Optive, Allergan), to provide both symptomatic relief and disease modification by addressing inflammation and lubrication[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclosporine + carboxymethylcellulose.